STLN
Starling Oncology, Inc.
+0.33 (+5.05%)6.86USD1.1M成交股數699M市值–本益比(近四季)1.2股價營收比+34.6%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 161M+54% | 147M | 137M+37% | 120M+22% | 104M+10% | – | 99.9M+22% | 98.6M+23% | 94.7M | 85.8M | 82.0M | 80.2M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | – | – | – | – | – | – | – | – | – | – | – | – |
| 銷售管理費用 | 29.9M | 28.2M | 25.3M | 26.9M | 25.4M | – | 26.6M | 27.9M | 28.5M | 28.1M | 28.2M | 28.7M |
| 營業利益 | −4.6M-53% | −6.5M | −8.1M-42% | −11.2M-31% | −9.9M-45% | – | −13.9M-1% | −16.4M+10% | −18.0M | −15.3M | −13.9M | −14.9M |
| 營業利益率 | -2.9% | -4.4% | -5.9% | -9.4% | -9.5% | – | -13.9% | -16.6% | -19.0% | -17.8% | -17.0% | -18.6% |
| 稅後淨利 | −9.8M-50% | −2.5M | −16.5M+2% | −17.0M+10% | −19.6M-2% | – | −16.1M-7% | −15.5M-8% | −19.9M | −18.8M | −17.4M | −16.9M |
| 淨利率 | -6.1% | -1.7% | -12.1% | -14.2% | -18.8% | – | -16.1% | -15.7% | -21.0% | -21.9% | -21.2% | -21.1% |
| 稀釋 EPS | -0.08-62% | -0.02 | -0.14-22% | -0.15-12% | -0.21-5% | – | -0.18-5% | -0.17-11% | -0.22 | -0.21 | -0.19 | -0.19 |
| 稀釋股數 | 103M | 102M | 97.5M | 93.2M | 77.1M | – | 75.5M | 74.7M | 74.2M | 73.7M | 73.5M | 74.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 41.1M | 30.3M | 27.7M | 30.3M | 39.7M | 49.7M | 47.4M | 36.4M | 36.1M | 33.5M | 27.5M | 28.9M |
| 應收帳款 | 66.3M | 58.1M | 59.6M | 55.7M | 49.3M | 48.3M | 54.5M | 54.0M | 58.8M | 42.4M | 48.4M | 46.4M |
| 存貨 | 20.0M | 24.3M | 18.9M | 15.8M | 12.3M | 10.0M | 10.1M | 11.3M | 11.6M | 13.7M | 12.2M | 12.2M |
| 總資產 | 178M | 168M | 164M | 160M | 164M | 173M | 179M | 180M | 205M | 209M | 218M | 230M |
| 有息負債 | 79.9M | 78.6M | 76.2M | 75.0M | 73.9M | 93.1M | 91.5M | 90.0M | 88.4M | 86.8M | 85.3M | 83.7M |
| 總負債 | 203M | 185M | 176M | 169M | 159M | 169M | 164M | 150M | 163M | 152M | 147M | 145M |
| 股東權益 | −24.9M | −16.3M | −12.3M | −9.0M | 5.1M | 3.6M | 15.5M | 29.2M | 41.3M | 57.0M | 71.8M | 84.7M |
| 負債比 | 114.0% | 109.7% | 107.5% | 105.6% | 96.9% | 97.9% | 91.4% | 83.7% | 79.8% | 72.7% | 67.1% | 63.2% |
| 淨現金(現金 − 有息負債) | −38.8M | −48.3M | −48.5M | −44.7M | −34.2M | −43.5M | −44.1M | −53.5M | −52.3M | −53.3M | −57.7M | −54.8M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.2M-155% | – | – | −5.0M-69% | 4.0M | – | – | −15.9M | – | – | – |
| 資本支出 | – | 1.0M | – | – | 328K | – | – | – | 610K | – | – | – |
| 自由現金流 | – | −3.3M | – | – | −5.3M-68% | – | – | – | −16.5M | – | – | – |
| 折舊攤銷 | 1.8M | 1.6M | 1.7M | 1.8M | 1.8M | – | 1.6M | 1.5M | 1.5M | 1.6M | 1.7M | 1.3M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2.2% | – | – | -5.1% | – | – | – | -17.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 503M
| Specialty Pharmacy | 269M | 53.5% | +49.6% |
|---|---|---|---|
| Patient Services | 229M | 45.5% | +11.8% |
| Clinical Trials And Other | 4.6M | 0.9% | -47.0% |
產品／服務2025 年度 · 503M
| Health Care Specialty Pharmacy | 269M | 53.5% | +49.6% |
|---|---|---|---|
| Fee For Service | 149M | 29.5% | +9.0% |
| Capitated Revenue | 80.5M | 16.0% | +17.2% |
| Clinical Research Trials And Other Revenue | 4.6M | 0.9% | -47.0% |
| Health Care Patient Service 小計 | 229M | 45.5% | +11.8% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 503M | +27.8% | 60.6B | 12,055.4% | -0.54 | −27.8M |
| FY2024 | 393M | +21.3% | 64.7B | 16,436.5% | -0.71 | −30.3M |
| FY2023 | 324M | +28.4% | −83.1M | -25.6% | -0.92 | −40.9M |
| FY2022 | 252M | +24.4% | 152K | 0.1% | -0.21 | −67.3M |
| FY2021 | 203M | +8.3% | −10.9M | -5.4% | -0.16 | −35.5M |
| FY2020 | 188M | – | −14.3M | -7.6% | -0.24 | −686K |